Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Modi, Dipenkumar  [Clear All Filters]
2023
Modi D, Alkassis S, Kim S, Kin A, Deol A, Ayash L, Ratanatharathorn V, Uberti JP. Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission. Leuk Lymphoma. 2023:1-10.
2022
Lee CJ, Wang T, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Auletta JJ, et al. Association of Chronic Graft-versus-Host Disease with Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. Transplant Cell Ther. 2022.
2021
Bhatt VRaj, Wang T, Chen K, Kitko CL, MacMillan ML, Pidala JA, Malki MMAl, Badawy SM, Beitinjaneh A, Ganguly S, et al. Chronic Graft-Versus-Host Disease, Non-Relapse Mortality and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A CIBMTR Analysis. Transplant Cell Ther. 2021.
Albanyan O, Alkassis S, Kim S, Kin A, Alavi A, Ayash L, Ratanatharathorn V, Modi D, Uberti JP, Deol A. Impact of pre-transplant induction therapy on outcomes of patients who undergo autologous stem cell transplantation for mantle cell lymphoma in first complete remission. Hematol Oncol Stem Cell Ther. 2021.
Modi D, Chi J, Kim S, Deol A, Ayash L, Ratanatharathorn V, Uberti JP. Outcomes of Fludarabine, Melphalan and Total Body Irradiation as a Reduced Intensity Conditioning Regimen in Matched Donor Allogeneic Peripheral Blood Stem Cell Transplantation: Outcomes of Flu-Mel-TBI. Transplant Cell Ther. 2021.
2019
Modi D, Surapaneni M, Kim S, Ayash L, Alavi A, Ratanatharathorn V, Deol A, Uberti JP. Allogeneic stem cell transplant provides durable response in peripheral T-cell lymphoma. Leuk Res. 2019;83:106171.
Modi D, Kim S, Surapaneni M, Ayash L, Alavi A, Ratanatharathorn V, Deol A, Uberti JP. R-BEAM versus Reduced Intensity Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma. Biol Blood Marrow Transplant. 2019.